>
Fa   |   Ar   |   En
   Animal models of diabetic macrovascular complications: Key players in the development of new therapeutic approaches  
   
نویسنده heinonen s.e. ,genové g. ,bengtsson e. ,hübschle t. ,åkesson l. ,hiss k. ,benardeau a. ,ylä-herttuala s. ,jönsson-rylander a.-c. ,gomez m.f.
منبع journal of diabetes research - 2015 - دوره : 2015 - شماره : 0
چکیده    Diabetes mellitus is a lifelong,incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease,stroke,and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). based on the current trends,the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. therefore,novel means to prevent and treat these complications are needed. under the auspices of the imi (innovative medicines initiative),the summit (surrogate markers for micro-and macrovascular hard end points for innovative diabetes tools) consortium is working on the development of novel animal models that better replicate vascular complications of diabetes and on the characterization of the available models. in the past years,with the high level of genomic information available and more advanced molecular tools,a very large number of models has been created. selecting the right model for a specific study is not a trivial task and will have an impact on the study results and their interpretation. this review gathers information on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development. © 2015 suvi e. heinonen et al.
آدرس dept. bioscience,cardiovascular and metabolic diseases,innovative medicines and early development,astrazeneca r and d, Sweden, division of vascular biology,department of medical biochemistry and biophysics,karolinska institutet, Sweden, department of clinical sciences,lund university diabetes centre (ludc),lund university, Sweden, randd diabetes division,translational medicine,sanofi-aventis, Germany, department of clinical sciences,lund university diabetes centre (ludc),lund university, Sweden, randd diabetes division,translational medicine,sanofi-aventis, Germany, department of biotechnology and molecular medicine,a.i. virtanen institute for molecular sciences,university of eastern finland, Finland, pharmaceutical division,pred,cv and metabolic disease,hoffmann-la roche, Switzerland, dept. bioscience,cardiovascular and metabolic diseases,innovative medicines and early development,astrazeneca r and d, Sweden, department of clinical sciences,lund university diabetes centre (ludc),lund university, Sweden
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved